Evidence map›Paper›PMID 38058181›Full record

ArticleHaematologica2024

Sickle cell disease, pregnancy, and COVID-19 in France:

Lydia H Pecker, Jerome Federspiel

Abstract readEditorialComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Haematologica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Lydia H PeckerDivision of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD USA; Department of Gynecology and Obstetrics, Johns Hopkins University School of Medicine, Baltimore, MD. lpecker1@jhmi.edu.
Jerome FederspielDivision of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, Duke University School of Medicine, Durham, NC, USA; Department of Population Health Sciences, Duke University School of Medicine, Durham, NC.

Funding

Clinical and genetic risk factors associated with adverse long-term health outcomes after curative therapies in individuals with sickle cell diseaseU01HL156620 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI DEBAUN, MICHAEL R., FITZHUGH, COURTNEY D · 2021 to 2025
$4.1M
Duke Women's Reproductive Health Research ScholarsK12HD103083 · NICHD · DUKE UNIVERSITY · PI Cindy Amundsen · 2020 to 2026
$2.2M
OVARIAN RESERVE IN POST-MENARCHAL FEMALES WITH SICKLE CELL ANEMIAK23HL146841 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI PECKER, LYDIA · 2020 to 2024
$1.2M
NHLBI NIH HHS K23 HL146841NHLBI NIH HHS U01 HL156620NICHD NIH HHS K12 HD103083
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Anemia, Sickle CellCOVID-19SARS-CoV-2FemaleFranceHumansPregnancyPregnancy Complications, HematologicPregnancy Complications, Infectious

Identifiers

PMID38058181
PMCPMC11063831

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.